Cargando…

Unique Flap Conformation in an HIV-1 Protease with High-Level Darunavir Resistance

Darunavir (DRV) is one of the most powerful protease inhibitors (PIs) for treating human immunodeficiency virus type-1 (HIV-1) infection and presents a high genetic barrier to the generation of resistant viruses. However, DRV-resistant HIV-1 infrequently emerges from viruses exhibiting resistance to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakashima, Masaaki, Ode, Hirotaka, Suzuki, Koji, Fujino, Masayuki, Maejima, Masami, Kimura, Yuki, Masaoka, Takashi, Hattori, Junko, Matsuda, Masakazu, Hachiya, Atsuko, Yokomaku, Yoshiyuki, Suzuki, Atsuo, Watanabe, Nobuhisa, Sugiura, Wataru, Iwatani, Yasumasa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737996/ https://www.ncbi.nlm.nih.gov/pubmed/26870021 http://dx.doi.org/10.3389/fmicb.2016.00061

Ejemplares similares

Quasispecies Analyses of the HIV-1 Near-full-length Genome With Illumina MiSeq
por: Ode, Hirotaka, et al.
Publicado: (2015)

Compound heterozygous TYK2 mutations underlie primary immunodeficiency with T-cell lymphopenia
por: Nemoto, Michiko, et al.
Publicado: (2018)

Phylodynamic Analysis Reveals CRF01_AE Dissemination between Japan and Neighboring Asian Countries and the Role of Intravenous Drug Use in Transmission
por: Shiino, Teiichiro, et al.
Publicado: (2014)

Structural basis of chimpanzee APOBEC3H dimerization stabilized by double-stranded RNA
por: Matsuoka, Tatsuya, et al.
Publicado: (2018)

Nanopore Sequencing for Characterization of HIV-1 Recombinant Forms
por: Mori, Mikiko, et al.
Publicado: (2022)

Cellular APOBEC3A deaminase drives mutations in the SARS-CoV-2 genome
por: Nakata, Yoshihiro, et al.
Publicado: (2023)

Molecular epidemiological features of SARS-CoV-2 in Japan, 2020–1
por: Ode, Hirotaka, et al.
Publicado: (2022)

Impact of long-term antiretroviral therapy on gut and oral microbiotas in HIV-1-infected patients
por: Imahashi, Mayumi, et al.
Publicado: (2021)

SARS-CoV-2 accessory protein ORF8 is secreted extracellularly as a glycoprotein homodimer
por: Matsuoka, Kazuhiro, et al.
Publicado: (2022)

Lack of Association between Intact/Deletion Polymorphisms of the APOBEC3B Gene and HIV-1 Risk
por: Imahashi, Mayumi, et al.
Publicado: (2014)

Molecular dynamics simulation in virus research
por: Ode, Hirotaka, et al.
Publicado: (2012)

Structural Features of Antiviral APOBEC3 Proteins are Linked to Their Functional Activities
por: Kitamura, Shingo, et al.
Publicado: (2011)

Nation-Wide Viral Sequence Analysis of HIV-1 Subtype B Epidemic in 2003–2012 Revealed a Contribution of Men Who Have Sex With Men to the Transmission Cluster Formation and Growth in Japan
por: Shiino, Teiichiro, et al.
Publicado: (2020)

Cytokines and Chemokines Involved in Hepatitis B Surface Antigen Loss in Human Immunodeficiency Virus/Hepatitis B Virus Coinfected Patients
por: Urata, Noboru, et al.
Publicado: (2021)

Antiviral Mechanism and Biochemical Basis of the Human APOBEC3 Family
por: Imahashi, Mayumi, et al.
Publicado: (2012)

A cell-free enzymatic activity assay for the evaluation of HIV-1 drug resistance to protease inhibitors
por: Matsunaga, Satoko, et al.
Publicado: (2015)

Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy
por: Nishizawa, Masako, et al.
Publicado: (2015)

SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity
por: Ozono, Seiya, et al.
Publicado: (2021)

The 4th and 112th Residues of Viral Capsid Cooperatively Modulate Capsid-CPSF6 Interactions of HIV-1
por: Saito, Akatsuki, et al.
Publicado: (2020)

saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern
por: Komori, Mai, et al.
Publicado: (2023)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir: Various toxicities and off-label use: 9 case reports
Publicado: (2020)

Inferring within-patient HIV-1 evolutionary dynamics under anti-HIV therapy using serial virus samples with vSPA
por: Hasegawa, Naoki, et al.
Publicado: (2009)

Production of HIV-1 vif mRNA Is Modulated by Natural Nucleotide Variations and SLSA1 RNA Structure in SA1D2prox Genomic Region
por: Nomaguchi, Masako, et al.
Publicado: (2017)

Antibody-like proteins that capture and neutralize SARS-CoV-2
por: Kondo, T., et al.
Publicado: (2020)

Dissecting Naturally Arising Amino Acid Substitutions at Position L452 of SARS-CoV-2 Spike
por: Tan, Toong Seng, et al.
Publicado: (2022)

Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study
por: Akahata, Wataru, et al.
Publicado: (2023)

Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations
por: Gutierrez‐Valencia, Alicia, et al.
Publicado: (2018)

Darunavir resistance spectrum in darunavir-na#239;ve patients harboring virological failure to antiretroviral therapy
por: Marcelin, AG, et al.
Publicado: (2010)

Two Genetic Determinants Acquired Late in Mus Evolution Regulate the Inclusion of Exon 5, which Alters Mouse APOBEC3 Translation Efficiency
por: Li, Jun, et al.
Publicado: (2012)

Combating HIV resistance – focus on darunavir
por: Tremblay, Cécile L
Publicado: (2008)

Role of darunavir in the management of HIV infection
por: Lascar, R Monica, et al.
Publicado: (2009)

Darunavir pharmacokinetics throughout pregnancy and postpartum
por: Lambert, John, et al.
Publicado: (2014)

Structures of Darunavir-Resistant HIV-1 Protease Mutant Reveal Atypical Binding of Darunavir to Wide Open Flaps
por: Zhang, Ying, et al.
Publicado: (2014)

Integrated Electrochemical Analysis System with Microfluidic and Sensing Functions
por: Satoh, Wataru, et al.
Publicado: (2008)

Multiple Pathways To Avoid Beta Interferon Sensitivity of HIV-1 by Mutations in Capsid
por: Sultana, Tahmina, et al.
Publicado: (2019)

Appropriate clinical use of darunavir 800 mg
por: Moorhouse, Michelle A., et al.
Publicado: (2018)

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

2482. Clinical Outcomes of Once-Daily Darunavir in Treatment-Experienced Patients with Darunavir Resistance Associated Mutations Through 48 Weeks of Treatment
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2v5sil7tk8s11v3ihhumjt4e1s